乙酰肝素酶
CCL19型
癌症研究
C-C趋化因子受体7型
A549电池
下调和上调
染色质免疫沉淀
转移
生物
肺癌
分子生物学
趋化因子受体
化学
癌症
医学
趋化因子
免疫学
病理
基因表达
发起人
炎症
基因
生物化学
遗传学
作者
Qingfu Zhang,Limei Sun,Liying Yin,Jian Ming,Siyang Zhang,Wenting Luo,Xueshan Qiu
出处
期刊:Tumor Biology
[SAGE]
日期:2013-05-06
卷期号:34 (5): 2703-2708
被引量:42
标识
DOI:10.1007/s13277-013-0822-z
摘要
CCL19/chemokine receptor 7 (CCR7) has been found to be associated with tumor growth, angiogenesis, invasion, and lymph node metastasis. Our previous study demonstrated that CCR7 overexpressed in non-small cell lung cancer (NSCLC) and had close relationship with tumor invasion and lymph node metastasis. However, the molecular mechanism of CCR7 promoting invasion of human NSCLC cells is still unclear. In this study, we demonstrated that human lung adenocarcinoma A549 cells treated with recombinant human CCL19 could obviously upregulate the expression of Sp1 and heparanase at both the mRNA and protein levels. After blockage of CCR7, Sp1 and heparanase expressions were inhibited. Following inhibition of Sp1, heparanase expression was downregulated. The analysis showed the promoter region of heparanase gene containing a number of potential sp1 binding sites (5′-GGGGC-3′). Chromatin immunoprecipitation analysis demonstrated that Sp1 could bind to the heparanase promoter. Cell invasion assays showed that the invasion ability of A549 cells was increased with CCL19 incubation compared to the control cells. These results suggested that CCL19/CCR7 may upregulate the expression of heparanase via Sp1 and contribute to the invasion of A549 cells.
科研通智能强力驱动
Strongly Powered by AbleSci AI